Publications by authors named "Ayman Zawadi"
Purpose: The microsatellite instability (MSI) or deficient mismatch repair (dMMR) phenotype is usually regarded as a single biologic entity, given the absence of comparative analyses regarding prognosis and response to chemotherapy between sporadic and familial dMMR cancers.
Patients And Methods: Patients with stage III colon cancers were randomly assigned to FOLFOX (leucovorin, fluorouracil, and oxaliplatin) with or without cetuximab in 2 large adjuvant phase III trials (N = 5,577). Among patients with MSI and exon 2 wild-type (WT) tumors, the prognostic and predictive impacts of sporadic versus familial dMMR cancers and V600E mutational status were determined.
Article Synopsis
- The study aimed to compare the effectiveness of adding induction chemotherapy (TPF) before cetuximab radiotherapy (cetux-RT) versus the standard concurrent chemoradiotherapy (CT-RT) for treating advanced head and neck cancer.
- A total of 370 patients participated, and results showed no significant difference in progression-free survival between the two treatment approaches, with both having similar outcomes.
- Although TPF led to lower rates of distant metastases, it also resulted in higher instances of severe side effects and treatment-related deaths, indicating that TPF plus cetux-RT did not provide additional benefits over the conventional CT-RT.*
Purpose To investigate the effect of adding concurrent chemotherapy (CT) to cetuximab plus radiotherapy (RT; CT-cetux-RT) compared with cetuximab plus RT (cetux-RT) in locally advanced squamous cell carcinoma of the head and neck (LA-SCCHN). Patients and Methods In this phase III randomized trial, patients with N0-2b, nonoperated, stage III or IV (nonmetastatic) LA-SCCHN were enrolled. Patients received once-daily RT up to 70 Gy with weekly cetuximab or with weekly cetuximab and concurrent carboplatin and fluorouracil (three cycles).
View Article and Find Full Text PDFImportance: The prognostic impact of DNA mismatch repair (MMR) status in stage III colon cancer patients receiving FOLFOX (folinic acid, fluorouracil, and oxaliplatin) adjuvant chemotherapy remains controversial.
Objective: To determine the association of MMR status with disease-free survival (DFS) in patients with stage III colon cancer treated with FOLFOX.
Design, Setting, And Participants: The evaluated biomarkers for MMR status were determined from prospectively collected tumor blocks from patients treated with FOLFOX in 2 open-label, phase 3 randomized clinical trials: NCCTG N0147 and PETACC8.